Breakthrough in COVID-19 Research: Nanobodies Against Emerging SARS-CoV-2 Variants

Strategic Insights -

Research conducted by the Institute for Stem Cell Science and Regenerative Medicine has led to the identification of an efficacious nanobody, N1.2, that blocks the entry of the SARS-CoV-2 spike protein into human host cells. This breakthrough has significant implications for the development of antiviral therapy against emerging SARS-CoV variants and other viruses.

Key Takeaways:

  • The research team used a nine-amino acid peptide from the receptor-binding motif of the spike protein as an epitope to screen nanobodies against SARS-CoV-2.
  • The identified nanobody, N1.2, exhibited a potent neutralizing effect against both the Wuhan and Omicron pseudotyped spike virus, with a bivalent version showing improved efficacy.
  • The approach used in this study can be widely extended to target other viruses and pathogens in the future.
  • The research utilized a mCherry fluorescence-based reporter assay to evaluate the neutralizing effect of the N1.2 nanobody.
  • The team involved in this research includes Rayees A. Ganie, Nivya Mendon, Shubham Kesarwani, Drisya Dileep, Sarika Sasi, Prakash Lama, Anchal Chandra, and Minhajuddin Sirajuddin from the Institute for Stem Cell Science and Regenerative Medicine.

Statistics:

  • The nine-amino acid peptide used as an epitope in this study was identified from the receptor-binding motif of the spike protein.
  • The N1.2 nanobody exhibited a more potent neutralizing effect against the Wuhan and Omicron pseudotyped spike virus compared to previous reports.
  • The bivalent version of the N1.2 nanobody showed improved efficacy against both the hCoV19 and Omicron-BA.1 pseudotyped spike virus.
  • The research team aimed to develop a rapid and efficient methodology for screening nanobodies against potential pathogenic targets.

Sources:

  • Nanobody derived using a peptide epitope from the spike protein receptor-binding motif inhibits entry of SARS-CoV-2 variants (Journal of Biological Chemistry, 2022;299(1):102732)
  • Journal of Biological Chemistry (Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands)
  • NewsRx. Institute for Stem Cell Science and Regenerative Medicine Reports Findings in COVID-19 (Nanobody derived using a peptide epitope from the spike protein receptor-binding motif inhibits entry of SARS-CoV-2 variants). Nanotechnology Weekly. January 9, 2023; p 4.